Media

Nordic Nanovector – Private placement successfully completed

Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016

Nordic Nanovector: Betalutin® in combination with rituximab demonstrates synergistic anti-tumour effect in preclinical non-Hodgkin lymphoma model

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients

Nordic Nanovector to Present at the Nordic-American Life Sciences Conference in New York

Strongbridge Biopharma plc Announces Promotion of Fredric Cohen, M.D., to Chief Medical Officer

Onxeo Strengthens AsiDNA Patent Protection in Europe

Wilson Therapeutics AB (publ) Interim Report January 1 – September 30, 2016

Nordic Nanovector ASA – Results for third quarter 2016